Degrader-antibody conjugates

Area of Science:

• Bioconjugation Chemistry
• Molecular Pharmacology
• Antibody-Drug Conjugate Technology

Background:

• Antibody-drug conjugates (ADCs) are established therapeutics.
• Degrader-antibody conjugates (DACs) represent a novel class of targeted therapeutics.
• DACs combine antibody-based targeting with targeted protein degradation.

Purpose of the Study:

• To provide a comprehensive review of the current degrader-antibody conjugate (DAC) field.
• To compare and contrast DACs with traditional antibody-drug conjugates (ADCs).
• To highlight strategies and challenges in DAC development.

Main Methods:

• Review of scientific literature and patent databases.
• Analysis of various linker chemistries and PROTAC payloads.
• Comparison of biological activity and degradation mechanisms.

Main Results:

• DACs can be constructed using diverse PROTAC payloads and E3 ligases.
• Various linker strategies are employed for DAC assembly.
• Challenges in DAC construction are identified and discussed.

Conclusions:

• Biologically active DACs can be successfully prepared.
• DACs offer a promising platform for targeted protein degradation.
• The field is advancing with diverse strategies and payloads.